使用常规细胞遗传学分析确定复杂的型是多发性骨髓瘤患者预后不良的因素
Hideki Uryu1, Yuko Mishima1, Yuko Ishihara1
1Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Journal of clinical and experimental hematopathology : JCEH
|March 27, 2024
概括
复杂型 (CK) 在多发性骨髓瘤 (MM) 中显著恶化预后,影响无进展和整体存活率. 单独高风险的细胞遗传异常并没有影响结果,但CK甚至在HRCAs的情况下也会使生存率恶化.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 细胞遗传学 细胞遗传学
背景情况:
- 高危细胞遗传异常 (HRCAs) 是众所周知的多发性骨髓瘤 (MM) 的预后因素.
- 其他染色体异常,特别是复杂型 (CK) 对MM预后的影响需要进一步澄清.
研究的目的:
- 研究HRCAs和CK对新诊断的MM患者治疗新药的无进展生存期 (PFS) 和整体生存期 (OS) 的独立和联合预后影响.
- 确定与CK相关的因素及其对MM结果的影响.
主要方法:
- 对110名新诊断的MM患者进行了回顾性分析,这些患者接受了新药治疗.
- 通过光现场杂交 (FISH) 来评估HRCAs (del{17p},t{4},14,t{14},16,增益/放大{1q}).
- 将CK定义为G带上的≥3个染色体异常;评估组间的PFS和OS差异.
主要成果:
- 患有HRCAs和没有HRCAs的患者的生存时间相似.
- 与没有CK的患者相比,CK患者的PFS (9个月 vs. 24个月) 和OS (29个月 vs. 97个月) 显着较差.
- 即使在患有HRCAs的患者中,CK也保持了其不良的预后影响;CK与高骨髓血细胞负担和ISS III阶段有关.
结论:
- 复杂型 (CK) 是多发性骨髓瘤预后不佳的重要独立预测因子,独立于HRCAs.
- CK与侵袭性疾病特征有关,包括高血细胞负担和晚期.
- 在MM中,CK的存在需要考虑加强治疗策略.
更多相关视频
14:30Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors
Published on: August 7, 2021
6.7K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
相关概念视频
01:17Karyotyping
60.2K
Overview
60.2K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:24Kaplan-Meier Approach
136
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
136